Filing identity and reporting period
Important entity mismatch: The supplied filing is First Light Acquisition Group, Inc.’s Form 10-Q for the quarter ended September 30, 2022—not a filing by Calidi Biotherapeutics, Inc. First Light was a blank-check company seeking a business combination; it had no operating revenue or operating business. The summary below reflects the supplied filing and should not be attributed to Calidi.
Financial results and liquidity
| Metric | Three months ended September 30, 2022 | Nine months ended September 30, 2022 |
|---|---|---|
| Operating costs | $1.06 million | $1.95 million |
| Net income | $494,000 | $6.12 million |
| Net cash used in operations | Not separately presented | $1.07 million |
- No operating revenue; reported income primarily reflected non-operating trust-account earnings and gains from remeasurement of warrant and forward-purchase liabilities. Nine-month warrant fair-value gain was $6.58 million; trust-account earnings were $1.27 million.
- Operating cash was $39,944 at quarter-end, down from $1.06 million at December 31, 2021. Working capital was negative $860,553, versus positive $1.07 million at year-end.
- Trust-account assets were $41.68 million, down from $230.00 million, following redemptions. Total liabilities were $10.37 million, including $460,000 of related-party promissory notes and an $8.05 million deferred underwriting fee payable upon a business combination.
- No long-term debt was reported. The filing states there were no off-balance-sheet arrangements.
Material changes and developments
- On September 13, stockholders approved extending the business-combination deadline from September 14 to December 14, 2022, with possible three-month extensions up to September 14, 2023.
- In connection with the extension, holders redeemed 18,871,976 Class A shares for $190.01 million. At September 30, 4,128,024 public shares remained, with $41.68 million in the trust account.
- The company recorded $1.51 million of third-quarter accretion to redeemable shares. Fair-value gains materially affected reported profit; these are not operating earnings.
Outlook, risks and unusual items
- Management said the company lacked resources to sustain operations for a year and disclosed substantial doubt about its ability to continue as a going concern. Sponsor support for working-capital loans was described as a commitment without a formal agreement.
- The company needed to complete a business combination by the applicable deadline or redeem public shares and liquidate. The filing reported $50 million of forward-purchase financing contemplated under an agreement, subject to conditions and payable concurrently with a business combination.
- Management cited possible adverse effects from COVID-19, inflation, rising interest rates, and the Russia-Ukraine war on its financial position and target search. It also highlighted uncertainty over a potential 1% federal excise tax on stock repurchases/redemptions beginning in 2023 and possible regulatory changes affecting SPACs.
- Disclosure controls were deemed ineffective because of a material weakness in accounting for complex financial instruments. Management reported remediation efforts were underway but provided no assurance they would succeed.
- The filing reported no legal proceedings. It gave no operating-company revenue or business-performance guidance.
Investor facts to verify
- Confirm the intended issuer: this filing names First Light Acquisition Group, not Calidi Biotherapeutics.
- Verify the business-combination deadline, any subsequent extensions or transaction developments, and the remaining trust balance after redemptions.
- Assess how much reported income came from noncash fair-value changes and trust interest rather than operations.
- Review the going-concern disclosure, related-party funding dependence, and the status of the control-deficiency remediation.
- Check the terms and conditions of the $50 million forward-purchase agreement and the deferred underwriting fee payable if a transaction closes.